FDA Gives Marketing Approval for Metozolv™ ODT (Orally Disintegrating Tablets)

September 8, 2009 – The FDA has granted marketing approval for the drug metoclopramide (Metozolv) 5mg and 10 mg orally disintegrating tablets. The drug, marketed by Salix Pharmaceuticals, is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults and the treatment of symptomatic documented GERD in adults who do not respond to conventional therapy. Therapy should not exceed 12 weeks in duration.

Metozolv dissolves in the mouth. This could be helpful for patients who need a pro-motility and anti-emetic drug, but are unable to swallow pills or are unable to maintain oral intake due to nausea and vomiting.

In clinical studies, the most frequently reported adverse events (equal or greater than 2% occurrence) were headache, nausea, fatigue, somnolence/drowsiness, and vomiting.

Important Safety Information

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose. Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

What are Phases?

Treatment trials or studies are in phases:

  • Phase 1 tests a new drug or treatment in a small group to evaluate its safety, determine a safe dosage range, and identify side effects;
  • Phase 2 expands the study to a larger group of people to see if it is effective and to further evaluate its safety;
  • Phase 3 expands the study to an even larger group of people to confirm its effectiveness, monitor side effects, and collect information that will allow the drug or treatment to be used safely.
News
Industry Treatment News
Eluxadoline (Viberzi)
Eosinophilic Esophagitis Study
Gattex
Linaclotide (Linzess)
Linaclotide Study for IBS in Children
Linaclotide Study for FC in Children
Medical News
Medical News - Archive
Events
Special Events & Meetings
Press Releases
2016-0801 Learn the Facts About Gastroparesis
2016-0405 Think You Have IBS? Find Out For Sure Before Starting a Treatment
2015-1123 Is it More than Simple Heartburn? Ask Your Doctor.
2015-7-30 Gastroparesis is a Hidden Medical Condition for Many
2015-0330 Online Survey Looks to Help Improve Outcomes for those with IBS
2014-1119 Persistent Heartburn May Be a Sign of GERD
2014-0826 Lack of Awareness of Gastroparesis May Impact Medical Care
2014-0326 IFFGD Marks IBS Awareness Month with Launch of Mobile App
2014-0225 IFFGD Research Grants to Study Gastroparesis
2013-1106 15 Tips for GERD Awareness Week
2013-0626 New DHA.org
2013-0412 IFFGD Presents 2013 Research Awards
2013-0401 Turning Attention to Returning Vets
2012-1109 Banish Frequent Heartburn by Burning More Calories
2012-0321 April is IBS Awareness Month: A Serious Issue for Veterans
2006-0418 Natl Commission
2001-1119 Heartburn or Heart Attack
2006-0321 Women's Health
2011-1130 Is Your Child's Reflux/Spitting Up A Point of Concern?
2006-0202 IBS or Something Else
2011-0412 IFFGD Research Award Winners
2005-1125 GERD Costs
2005-0412 IBS Awareness
2011-0329 IBS Signs You Should Not Ignore
2010-1118 GERD Difference
2004-1125 Heartburn & Heartache
2004-0929 Norton Honored
2009-1109 GERD at Night
2010-0517 US House Resolution for IBS
2010-1001 Heartburn or GERD?
2006-1116 GERD & Holidays
2007-0401 IBS Myths
2009-0417 IFFGD Research Award Recipients
2004-0525 IBS Travel Tips
2007-1118 When Is Simple Heartburn Not So Simple?
2008-0331 Dealing with Digestive Disorders
2004-0101 IFFGD Conference
2004-0408 IBS Medical Care
2007-0718 Proposed FDA Funding Applauded
2003-1117 GERD Treatment
2003-0401 IFFGD Research Awards
2003-0401 IBS Awareness
2002-1102 Heartburn Caution
2002-0423 IBS in Real World
2002-0423 IBS-C Treatment
2002-0402 IBS & Lost Potential
2001-0322 Patients First
1998-0401 IBS Millions Suffer
1997-1114 Research & Women's Health
Commentary
Misunderstood Functional GI Disorders
IBS is No Joking Matter
For Media
Reporters' Guides
Media Contact Form

Our Mission

healthy family

Education and Research

Our mission is to inform, assist and support people affected by gastrointestinal (GI) disorders.

IFFGD works with patients, families, physicians, health care professionals, and others to broaden understanding about gastrointestinal disorders and support or encourage research.

Awareness Activities & Accomplishments

Advocacy Activities

IFFGD Research Award